Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab

Ahmed Elmoursi, Terrence A. Barrett, Courtney Perry

Research output: Contribution to journalLetterpeer-review

14 Scopus citations
Original languageEnglish
Pages (from-to)e62-e63
JournalInflammatory Bowel Diseases
Volume26
Issue number7
DOIs
StatePublished - Jun 18 2020

Bibliographical note

Funding Information:
From the Division of Gastroenterology, Department of Internal Medicine, University of Kentucky, USA Supported by: CP is supported by the National Institutes of Health, Grant TL1TR001997 of CCTS funding. The authors’ work is also supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R21DK118954. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported in part by Merit Review Award #I01CX001353 to TAB from the United States Department of Veterans Affairs Laboratory Research and Development Program.

Keywords

  • Crohn's disease
  • double biologic therapy (DBT)
  • stricture
  • ustekinumab
  • vedolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab'. Together they form a unique fingerprint.

Cite this